Lanfil DX 60 Capsule MR contains Dexlansoprazole 60 mg, a proton pump inhibitor (PPI) indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-related disorders. Dexlansoprazole works by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. The modified-release formulation allows for a dual delayed-release mechanism, providing prolonged acid suppression and improved symptom control over a 24-hour period. This pharmacokinetic profile enhances patient compliance by enabling once-daily dosing. Lanfil DX 60 Capsule MR is effective in healing erosive esophagitis, maintaining healed esophagitis, and managing symptoms such as heartburn and regurgitation associated with GERD. It is also utilized in the management of Zollinger-Ellison syndrome and other conditions requiring sustained acid suppression. The medication should be administered orally, preferably before meals, and dosage adjustments may be necessary based on clinical response and patient tolerance. Common adverse effects include headache, diarrhea, abdominal pain, and nausea. Caution is advised in patients with hepatic impairment, and long-term use should be monitored due to potential risks such as vitamin B12 deficiency and bone fractures. Lanfil DX 60 Capsule MR should be used under medical supervision with appropriate diagnostic evaluation.